Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits

Circulation Research
J A AuchampachR Bolli

Abstract

To examine the cardioprotective role of A3 adenosine receptors during myocardial ischemia/reperfusion injury, we tested the effect of N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA), a potent and selective A3 adenosine receptor agonist, in models of myocardial stunning and infarction in chronically instrumented conscious rabbits. In phase I (studies of myocardial stunning), rabbits were subjected to six 4-minute coronary occlusions, each separated by 4-minute reperfusion periods, after which the recovery of systolic wall thickening was measured (ultrasonic crystals). In phase II (studies of myocardial infarction), rabbits were subjected to a 30-minute coronary occlusion followed by 3 days of reperfusion. In both phases, IB-MECA was administered as an intravenous bolus (100 micrograms/kg) 10 minutes before the first coronary occlusion. This dose of IB-MECA was determined in pilot studies to have no effect on heart rate, arterial blood pressure, or plasma histamine concentration in rabbits. In phase I, IB-MECA markedly improved the recovery of wall thickening after the six occlusion/reperfusion cycles, and this effect was sustained throughout the 5-hour observation period; the total deficit of wall thickening (a measure...Continue Reading

References

Nov 6, 1975·The New England Journal of Medicine·S F Vatner, E Braunwald
Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Q Y ZhouO Civelli
Nov 15, 1990·Biochemical and Biophysical Research Communications·J M HerbertJ P Maffrand
Feb 1, 1990·The American Journal of Physiology·R J Paul
Jan 1, 1990·Journal of Molecular and Cellular Cardiology·R D LasleyR M Mentzer
Jun 1, 1988·Naunyn-Schmiedeberg's Archives of Pharmacology·M J LohseM Grifantini
May 1, 1982·Journal of Cardiovascular Pharmacology·S R JollyB R Lucchesi
Jul 1, 1995·British Journal of Pharmacology·J P HannonJ R Fozard
Mar 4, 1994·Journal of Medicinal Chemistry·C Gallo-RodriguezP J van Galen
Feb 1, 1994·Current Opinion in Immunology·L B Schwartz
Oct 7, 1993·Biochimica Et Biophysica Acta·F G Sajjadi, G S Firestein
Jun 1, 1996·Journal of Molecular and Cellular Cardiology·P J RiceC E Ganote
Jul 1, 1995·Drugs of the Future·Kenneth A JacobsonDag K J E von Lubitz

❮ Previous
Next ❯

Citations

Nov 14, 2007·Basic Research in Cardiology·Michael V Cohen, James M Downey
May 25, 2010·Cardiovascular Drugs and Therapy·Derek J Hausenloy, Derek M Yellon
Jul 7, 2007·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Øyvind JakobsenDag G Sørlie
Oct 3, 2003·European Journal of Pharmacology·Helen L MaddockKenneth J Broadley
Sep 2, 2000·The Annals of Thoracic Surgery·D BelhommeP Menasché
Jul 3, 1999·The Annals of Thoracic Surgery·V H ThouraniJ Vinten-Johansen
Jun 14, 2002·European Journal of Pharmacology·Robert De JongeJan W De Jong
Feb 13, 1999·European Journal of Pharmacology·D K Von Lubitz
Jun 4, 1999·European Journal of Pharmacology·D K von Lubitz
Jul 7, 2000·Pharmacology & Therapeutics·A NakanoJ M Downey
Mar 18, 2000·Pharmacology & Therapeutics·M E Olah, G L Stiles
Jul 4, 1998·Trends in Pharmacological Sciences·K A Jacobson
Mar 7, 2006·Nature Reviews. Drug Discovery·Kenneth A Jacobson, Zhan-Guo Gao
Nov 25, 2003·The Journal of Pharmacology and Experimental Therapeutics·John A AuchampachGarrett J Gross
Oct 21, 2011·The Journal of Pharmacology and Experimental Therapeutics·Lili DuJohn A Auchampach
Jun 9, 2000·Annual Review of Physiology·M V CohenJ M Downey
Jul 12, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Enbo ZhanRobert D Lasley
Jul 27, 2002·Circulation Research·Richard G BlackJohn A Auchampach
Oct 22, 2008·Circulation·Beverly A Rothermel, Joseph A Hill
Apr 21, 2006·Critical Care : the Official Journal of the Critical Care Forum·Idit MatotKenneth A Jacobson
Jul 11, 2001·Journal of Molecular and Cellular Cardiology·V ShneyvaysA Shainberg
Jun 15, 2013·Pharmacology & Therapeutics·John P HeadrickJason N Peart
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·B T Liang, K A Jacobson
Apr 14, 2010·Bioorganic & Medicinal Chemistry·Shane M DevinePeter J Scammells
Aug 6, 2002·Cardiovascular Research·Ryan M FryerGarrett J Gross
Dec 18, 2001·Journal of Cardiovascular Pharmacology·Jason PeartJohn P Headrick
Nov 25, 2005·Journal of Cardiovascular Pharmacology·Zhelong XuJames M Downey
Nov 6, 2010·Journal of Cardiovascular Pharmacology·Jun SasamoriKouichi Tanonaka
May 5, 2001·Expert Opinion on Pharmacotherapy·R J GuminaA Terzic
Nov 27, 2015·The Journal of Pharmacology and Experimental Therapeutics·Jesse Lea CarlinMarc L Reitman
Dec 14, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Bella ChanyshevKenneth A Jacobson
Oct 29, 2011·Drug Discovery Today·Pnina FishmanKenneth A Jacobson
Feb 6, 2010·Journal of Molecular and Cellular Cardiology·Zhi-Dong GeJohn A Auchampach

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.